Guided Therapeutics, Inc.

Equities

GTHP

US40171F5017

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 15:03:01 23/05/2024 BST			5-day change	1st Jan Change
0.109 ^USD	+35.40%		+9.00%	-28.99%

05-14	Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Guided Therapeutics, Inc Provides Sales Guidance for the First Quarter and Full Year 2016

January 21, 2016 at 02:49 pm

Guided Therapeutics Inc. provided sales guidance for the first quarter and full year 2016. For the first quarter, the company's sales are expected to exceed record fourth quarter of 2015.

For the year 2016, the company anticipated sales of $3 million to $5 million.

Latest news about Guided Therapeutics, Inc.

Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval	11-20	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Guided Therapeutics, Inc. Announces CEO Changes	09/03/23	CI
Guided Therapeutics, Inc. Announces Executive Changes	09/03/23	CI
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval	21/12/22	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan	09/11/22	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Guided Therapeutics, Inc. Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan	20/07/22	CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Guided Therapeutics, Inc. Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740	31/03/22	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	29/03/22	CI
Guided Therapeutics, Inc. Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China	17/11/21	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China	19/08/21	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	18/08/21	CI
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements	20/07/21	CI
Guided Therapeutics, Inc. announced that it has received $1.13 million in funding	02/06/21	CI

Chart Guided Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Companyâs primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
GUIDED THERAPEUTICS, INC.	-28.99%	4.49M
THERMO FISHER SCIENTIFIC	+10.42%	226B
DANAHER CORPORATION	+14.15%	198B
INTUITIVE SURGICAL, INC.	+18.33%	142B
BOSTON SCIENTIFIC CORPORATION	+29.38%	111B
SIEMENS HEALTHINEERS AG	+2.09%	65.26B
EDWARDS LIFESCIENCES CORPORATION	+14.67%	54.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.68%	50.94B
AGILENT TECHNOLOGIES, INC.	+8.56%	44.8B
GE HEALTHCARE TECHNOLOGIES INC.	+3.13%	36.8B

Other Advanced Medical Equipment & Technology